Brensocatib has no effect on clinical outcomes in COVID-19 | The latest news for doctors, nurses and pharmacists | Respirology
Results from the STOP-COVID trial presented at ERS 2022 showed no clinical benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared to placebo in patients hospitalized with COVID-19 in the UK. “[T]retreatment with brensocatib for 28 days was associated with worse clinical status on the WHO 7-point ordinal scale* at the end of treatment than …